Tralokinumab Significantly Reduces Work Productivity Impairment and Daily Activity Impairment in Adults With Atopic Dermatitis and Moderate-to-Severe Hand Involvement

Main Article Content

Benjamin Ehst
Oregon Medical Research Center, Portland, Oregon, USA

Leon Kircik
Icahn School of Medicine at Mount Sinai, New York, New York, USA

Andrei Metelitsa
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

Sebastian Volc
Department of Dermatology, University Hospital Tübingen, University of Tübingen, Tübingen, Germany

Sonja Molin
Department of Dermatology, Venerology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany; Division of Dermatology, Queen's University, Kingston, Canada

Pierre Johansen
LEO Pharma A/S, Ballerup, Denmark

Farzaneh Safavimanesh
LEO Pharma A/S, Ballerup, Denmark

Ann-Marie Tindberg
LEO Pharma A/S, Ballerup, Denmark

April Armstrong
University of California Los Angeles, Los Angeles, California, USA

Keywords

Tralokinumab, WPAI, work productivity and activity impairment, atopic dermatiits, hand involvement

Abstract

N/A

References

1. Lio PA, et al. J Drugs Dermatol. 2020;19(10):943-8.

2. Silverberg JI, et al. J Am Acad Dermatol. 2023;89(3):519-28.

3. Port LR, Brunner PM. Dermatol Clin. 2024;42(4):619-23.

4. Bieber T. Allergy. 2020;75(1):54-62.

5. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-49.

6. Paller AS, et al. JAMA Dermatol. 2023;159(6):596-605.

7. Blauvelt A, et al. J of Skin. 2025;9(2):s574.

8. Ehst B, et al. Acta Derm Venereol. 2025;105:44-5.

Article Sidebar

PDF
Published
2026-03-10
DOI: https://doi.org/10.25251/mjfdzc48

Article Details

How to Cite
1.
Tralokinumab Significantly Reduces Work Productivity Impairment and Daily Activity Impairment in Adults With Atopic Dermatitis and Moderate-to-Severe Hand Involvement. J of Skin. 2026;10(2):s726. doi:10.25251/mjfdzc48
Issue
Vol. 10 No. 2 (2026): March 2026 Issue
Section
Poster Presentations at 2026 Winter Clinical Miami Dermatology Conference®
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>